Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017

HA. van Dorland, MM. Taleghani, K. Sakai, KD. Friedman, JN. George, I. Hrachovinova, PN. Knöbl, AS. von Krogh, R. Schneppenheim, I. Aebi-Huber, L. Bütikofer, CR. Largiadèr, Z. Cermakova, K. Kokame, T. Miyata, H. Yagi, DR. Terrell, SK. Vesely, M....

. 2019 ; 104 (10) : 2107-2115. [pub] 20190221

Language English Country Italy

Document type Clinical Trial, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20025610

Grant support
K01 HL135466 NHLBI NIH HHS - United States

Congenital thrombotic thrombocytopenic purpura is an autosomal recessive inherited disease with a clinically heterogeneous course and an incompletely understood genotype-phenotype correlation. In 2006, the Hereditary TTP Registry started recruitment for a study which aimed to improve the understanding of this ultra-rare disease. The objective of this study is to present characteristics of the cohort until the end of 2017 and to explore the relationship between overt disease onset and ADAMTS13 activity with emphasis on the recurring ADAMTS13 c.4143_4144dupA mutation. Diagnosis of congenital thrombotic thrombocytopenic purpura was confirmed by severely deficient ADAMTS13 activity (≤10% of normal) in the absence of a functional inhibitor and the presence of ADAMTS13 mutations on both alleles. By the end of 2017, 123 confirmed patients had been enrolled from Europe (n=55), Asia (n=52, 90% from Japan), the Americas (n=14), and Africa (n=2). First recognized disease manifestation occurred from around birth up to the age of 70 years. Of the 98 different ADAMTS13 mutations detected, c.4143_4144dupA (exon 29; p.Glu1382Argfs*6) was the most frequent mutation, present on 60 of 246 alleles. We found a larger proportion of compound heterozygous than homozygous carriers of ADAMTS13 c.4143_4144dupA with overt disease onset at < 3 months of age (50% vs 37%), despite the fact that ADAMTS13 activity was <1% in 18 of 20 homozygous, but in only 8 of 14 compound heterozygous carriers. An evaluation of overt disease onset in all patients with an available sensitive ADAMTS13 activity assay (n=97) shows that residual ADAMTS13 activity is not the only determinant of age at first disease manifestation. Registered at clinicaltrials.gov identifier NCT01257269.

Blood Center University Hospital Ostrava Ostrava Czech Republic

CTU Bern University of Bern Bern Switzerland

Department of Biostatistics Epidemiology University of Oklahoma Health Sciences Center Oklahoma City OK USA

Department of Blood Transfusion Medicine Nara Medical University Kashihara Japan

Department of Blood Transfusion Medicine Nara Medical University Kashihara Japan Department of Hematology Nara Prefecture General Medical Center Nara Japan

Department of Blood Transfusion Medicine Nara Medical University Kashihara Japan Japanese Red Cross Kinki Block Blood Center Ibaraki Osaka Japan

Department of Hematology and Central Hematology Laboratory Inselspital Bern University Hospital Bern Switzerland

Department of Hematology and Central Hematology Laboratory Inselspital Bern University Hospital Bern Switzerland Center for Thrombosis and Hemostasis University Medical Center Mainz Mainz Germany

Department of Hematology and Central Hematology Laboratory Inselspital Bern University Hospital Bern Switzerland Department for BioMedical Research University of Bern Bern Switzerland

Department of Hematology St Olavs Hospital Trondheim University Hospital Trondheim Norway

Department of Molecular Pathogenesis National Cerebral and Cardiovascular Center Suita Japan

Department of Molecular Pathogenesis National Cerebral and Cardiovascular Center Suita Japan Department of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita Japan

Department of Paediatric Haematology and Oncology University Medical Centre Hamburg Eppendorf Hamburg Germany

Division of Hematology and Hemostasis Department of Medicine 1 Medical University of Vienna Austria

Division of Hematology and Oncology Medical College of Wisconsin Milwaukee WI USA

NRL for Hemostasis Institute of Hematology and Blood Transfusion Prague Czech Republic

University Institute of Clinical Chemistry Inselspital Bern University Hospital Bern Switzerland

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025610
003      
CZ-PrNML
005      
20201222160312.0
007      
ta
008      
201125s2019 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2019.216796 $2 doi
035    __
$a (PubMed)30792199
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a van Dorland, Hendrika A $u Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland. Department for BioMedical Research, University of Bern, Bern, Switzerland.
245    14
$a The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017 / $c HA. van Dorland, MM. Taleghani, K. Sakai, KD. Friedman, JN. George, I. Hrachovinova, PN. Knöbl, AS. von Krogh, R. Schneppenheim, I. Aebi-Huber, L. Bütikofer, CR. Largiadèr, Z. Cermakova, K. Kokame, T. Miyata, H. Yagi, DR. Terrell, SK. Vesely, M. Matsumoto, B. Lämmle, Y. Fujimura, JA. Kremer Hovinga, Hereditary TTP Registry,
520    9_
$a Congenital thrombotic thrombocytopenic purpura is an autosomal recessive inherited disease with a clinically heterogeneous course and an incompletely understood genotype-phenotype correlation. In 2006, the Hereditary TTP Registry started recruitment for a study which aimed to improve the understanding of this ultra-rare disease. The objective of this study is to present characteristics of the cohort until the end of 2017 and to explore the relationship between overt disease onset and ADAMTS13 activity with emphasis on the recurring ADAMTS13 c.4143_4144dupA mutation. Diagnosis of congenital thrombotic thrombocytopenic purpura was confirmed by severely deficient ADAMTS13 activity (≤10% of normal) in the absence of a functional inhibitor and the presence of ADAMTS13 mutations on both alleles. By the end of 2017, 123 confirmed patients had been enrolled from Europe (n=55), Asia (n=52, 90% from Japan), the Americas (n=14), and Africa (n=2). First recognized disease manifestation occurred from around birth up to the age of 70 years. Of the 98 different ADAMTS13 mutations detected, c.4143_4144dupA (exon 29; p.Glu1382Argfs*6) was the most frequent mutation, present on 60 of 246 alleles. We found a larger proportion of compound heterozygous than homozygous carriers of ADAMTS13 c.4143_4144dupA with overt disease onset at < 3 months of age (50% vs 37%), despite the fact that ADAMTS13 activity was <1% in 18 of 20 homozygous, but in only 8 of 14 compound heterozygous carriers. An evaluation of overt disease onset in all patients with an available sensitive ADAMTS13 activity assay (n=97) shows that residual ADAMTS13 activity is not the only determinant of age at first disease manifestation. Registered at clinicaltrials.gov identifier NCT01257269.
650    12
$a protein ADAMTS13 $x krev $x genetika $7 D000071120
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a věk při počátku nemoci $7 D017668
650    _2
$a senioři $7 D000368
650    12
$a alely $7 D000483
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a ženské pohlaví $7 D005260
650    12
$a heterozygot $7 D006579
650    12
$a homozygot $7 D006720
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a mutace $7 D009154
650    12
$a trombotická trombocytopenická purpura $x enzymologie $x genetika $7 D011697
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Taleghani, Magnus Mansouri $u Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland.
700    1_
$a Sakai, Kazuya $u Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan.
700    1_
$a Friedman, Kenneth D $u Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
700    1_
$a George, James N $u Department of Biostatistics Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
700    1_
$a Hrachovinova, Ingrid $u NRL for Hemostasis, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Knöbl, Paul N $u Division of Hematology and Hemostasis, Department of Medicine 1, Medical University of Vienna, Austria.
700    1_
$a von Krogh, Anne Sophie $u Department of Hematology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
700    1_
$a Schneppenheim, Reinhard $u Department of Paediatric Haematology and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Aebi-Huber, Isabella $u Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland. Department for BioMedical Research, University of Bern, Bern, Switzerland.
700    1_
$a Bütikofer, Lukas $u CTU Bern, University of Bern, Bern, Switzerland.
700    1_
$a Largiadèr, Carlo R $u University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland.
700    1_
$a Cermakova, Zuzana $u Blood Center, University Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Kokame, Koichi $u Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Suita, Japan.
700    1_
$a Miyata, Toshiyuki $u Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Suita, Japan. Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
700    1_
$a Yagi, Hideo $u Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan. Department of Hematology, Nara Prefecture General Medical Center, Nara, Japan.
700    1_
$a Terrell, Deirdra R $u Department of Biostatistics Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
700    1_
$a Vesely, Sara K $u Department of Biostatistics Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
700    1_
$a Matsumoto, Masanori $u Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan.
700    1_
$a Lämmle, Bernhard $u Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland. Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany.
700    1_
$a Fujimura, Yoshihiro $u Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan. Japanese Red Cross Kinki Block Blood Center, Ibaraki, Osaka, Japan.
700    1_
$a Kremer Hovinga, Johanna A $u Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland johanna.kremer@msel.ch. Department for BioMedical Research, University of Bern, Bern, Switzerland.
710    2_
$a Hereditary TTP Registry
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 104, č. 10 (2019), s. 2107-2115
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30792199 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222160307 $b ABA008
999    __
$a ok $b bmc $g 1599755 $s 1116296
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 104 $c 10 $d 2107-2115 $e 20190221 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
GRA    __
$a K01 HL135466 $p NHLBI NIH HHS $2 United States
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options